Lentigen Corporation and ZGene A/S have announced that they have entered into an exclusive license agreement whereby Lentigen will obtain an exclusive license to certain specified proprietary ZGene multisubstrate kinase genes for certain indications.
These genes will allow Lentigen to create lentiviral vectors with increased safety by providing the capability to eliminate genetically modified cells from the body, if required.
Lentigen will be able to provide this safety feature to clients who purchase its custom lentiviral vectors.
ZGene will receive an upfront payment and additional milestone payments based on development and commercialization, as well as royalty payments on resulting products.
"This license agreement represents another important step in Lentigen's development," remarked Dr. Boro Dropulic, Founder and CEO of Lentigen.
"We believe that these genes will provide lentiviral vector technology with additional safety features not present in retroviral and lentiviral vectors currently under evaluation in human clinical trials."
"Lentigen aims to increase the safety of Lentiviral vector technology by the acquisition of technologies and by its own internal research and development efforts."
Zoran Gojkovic, CEO of ZGene, said, "This agreement is another commercial validation of our technology."
"Since the founding of the company, we have been purposefully and successfully expanding our gene portfolio to ensure that this technology remains at the forefront of drug activation."
"I am excited that Lentigen will combine our genes with lentiviral delivery and hope that this work will pave the way for better and safer treatments."